WO2011067317A1 - Compositions pharmaceutiques pour la stimulation des cellules souches - Google Patents

Compositions pharmaceutiques pour la stimulation des cellules souches Download PDF

Info

Publication number
WO2011067317A1
WO2011067317A1 PCT/EP2010/068700 EP2010068700W WO2011067317A1 WO 2011067317 A1 WO2011067317 A1 WO 2011067317A1 EP 2010068700 W EP2010068700 W EP 2010068700W WO 2011067317 A1 WO2011067317 A1 WO 2011067317A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
previous
pharmaceutical
fgf
stem cells
Prior art date
Application number
PCT/EP2010/068700
Other languages
English (en)
Inventor
Roland Gordon-Beresford
Vinciane Gaussin
Jean-Pierre Latere Dwan'isa
Christian Homsy
Original Assignee
Cardio3 Biosciences S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ599930A priority Critical patent/NZ599930A/en
Priority to CA2781493A priority patent/CA2781493A1/fr
Priority to RU2012120834/15A priority patent/RU2012120834A/ru
Priority to CN201080053800XA priority patent/CN102711798A/zh
Priority to MX2012005976A priority patent/MX2012005976A/es
Priority to EP10790375.9A priority patent/EP2506867B1/fr
Application filed by Cardio3 Biosciences S.A. filed Critical Cardio3 Biosciences S.A.
Priority to AU2010326633A priority patent/AU2010326633A1/en
Priority to JP2012541498A priority patent/JP2013512877A/ja
Priority to BR112012013164A priority patent/BR112012013164A2/pt
Publication of WO2011067317A1 publication Critical patent/WO2011067317A1/fr
Priority to IL219901A priority patent/IL219901A0/en
Priority to US13/484,956 priority patent/US20120301538A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates generally to pharmaceutical compositions suitable for targeting tissues and/or organs.
  • it relates to the treatment of heart diseases through administration of stem cell- stimulating agents to the heart of an individual in need of heart tissue regeneration.
  • it discloses the use of such stem cell-stimulating agents to improve the regeneration of cardiac tissue from cardiac stem cells in vivo.
  • Myocardial infarction results in loss of cardiomyocytes, scar formation, ventricular remodeling, and eventually heart failure.
  • Pharmacologic, catheter-based, and surgical interventions have led to improved survival of patients with coronary artery disease (CAD), although they fail to regenerate dead myocardium. Consequently, reduced mortality is accompanied by increased morbidity because of ischemic heart failure.
  • CAD coronary artery disease
  • stem cell-based therapy has emerged as a potential new strategy for cardiac repair (Dimmeler S. et a/., J Clin Invest 2005, 1 1 , 572-583).
  • the optimal source of cells for repairing damaged myocardium is a topic of intense research. Important features of stem cells for cardiac regeneration include self renewal, clonogenicity, and the ability to differentiate into cardiomyocytes, endothelial cells and vascular smooth muscle cells.
  • BM-derived stem/progenitor cells for cardiac reparative therapy in animal studies, such as lineage negative (tin neg) c-kit positive (c-kit pos) BM stem cells, (Orlic et a/., Nature 2001 ; 410: 701 -705; Kajstura et a/., Circ. Res.
  • BM-derived mesenchymal stem cells MSCs
  • EPCs endothelial progenitor cells
  • CSCs resident cardiac stem cells
  • Myocardial repair requires the formation of new myocytes and coronary vessels, and it cannot be accomplished by a cell already fully committed to the myocyte lineage.
  • myocytes In the presence of an infarct, the generation of myocytes alone cannot restore contractile performance in the akinetic region; myocytes will not grow or survive in the absence of vessel formation.
  • Arterioles are critical for blood supply, and oxygen delivery is controlled by the capillary network.
  • neovasculogenesis alone would not restore the dead myocardium or reinstitute contractile activity in the infarcted portion of the ventricular wall.
  • CSCs injected locally in the infarcted myocardium of animals repaired the necrotic tissue and improve ventricular function (Beltrami et a/., Cell 2003; 1 14: 763-776; Bearzi et a/., Proc Natl Sci USA 2007 ; 104 : 14068-14073) has formed the basis of a new paradigm in which CSCs are implicated in the normal renewal of myocytes, endothelial cells, smooth muscle cells, and fibroblasts.
  • new hypotheses have to be raised to move the field in a direction that defines CSCs therapy clinically on an individual basis.
  • the present invention provides a totally novel approach to stimulate in vivo resident CSCs and, in one aspect, to commit them into the cardiac lineage, particularly to obtain from them a significant number of satisfactorily functional cells with hallmark features of cardiomyocytes.
  • the invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem cells-stimulating-agents and at least one pharmaceutically acceptable excipient.
  • Said at least two stem cells-stimulating-agents may be selected in the group consisting of TGF -1 , BMP-4, FGF-2, IGF-1 , Activin-A, alpha- thrombin, Cardiotrophin 1 , Cardiogenol C and mixtures thereof.
  • said at least two stem cells-stimulating-agents may be selected in the group consisting of TGF -1 , BMP-4, FGF-2, IGF-1 , Activin-A, Cardiotrophin 1 , Cardiogenol C and mixtures thereof.
  • the invention also relates to a pharmaceutical cocktail comprising a pharmaceutical composition (B) according to the present invention and a composition (A) comprising at least one pharmaceutically active substance.
  • the composition or cocktail of the present invention allows to provide stimulating agent-guided stem cells which means that resident cardiac stem cells, after having been put into contact with the composition or cocktail, are stimulated to enter into differentiation. Hence, the stimulated stem cells may be committed into a cardiac lineage and may become a cardiomyocyte.
  • stimulation or stimulating refers to recruitment, proliferation, survival and/or differentiation of stem cells.
  • cardiac tissue and “myocardium” refer to myocytes, blood vessels and fibroblasts.
  • CSCs Cardiac stem cells'
  • 'cardiac progenitor cells' 'resident cardiac stem cells' or 'resident cardiac progenitor cells' designate stem cells which are present in the myocardium. They are self-renewing, clonogenic, multipotent and may generate myocardium.
  • a 'stem cells stimulating agent' is an agent which improves the ability of stem cells, to be recruited to the site to be regenerated, to proliferate and to differentiate into cardiac tissue.
  • a 'stem cells stimulating agent composition' is a composition comprising at least two stem cell stimulating agents.
  • a 'stimulating agent-guided stem cell' is a stem cell which was in contact with a stem cell stimulating agent composition as defined above and further enters into differentiation i.e. is committed into the cardiac lineage.
  • the 'differentiation' is the process by which a less specialized cell becomes a more specialized cell.
  • the pharmaceutical composition (B) may comprise at least five stem cells-stimulating-agents selected in the group consisting of TGF -1 , BMP-4, FGF-2, IGF-1 , Activin-A, Cardiotrophin 1 , Cardiogenol C and mixtures thereof.
  • the pharmaceutical composition (B) may comprise TGF -1 , BMP-4, FGF-2, IGF-1 , Activin-A, Cardiotrophin 1 , and Cardiogenol C.
  • said pharmaceutical composition (B) may further optionally comprise alpha-thrombin.
  • Said pharmaceutical composition (B) may further comprise thrombin inhibitors, such as hirudin, bivalirudin, lepirudin, deirudin, argatroban, melagatran, ximelagatran, dabigatran, and heparin.
  • Alpha-thrombin is a coagulant agent.
  • said pharmaceutical composition (B) may optionally be free of alpha-thrombin.
  • the pharmaceutical composition (B) of the present invention may further comprise at least one substance selected in the group consisting of growth factors, cytokines, hormones and combinations thereof.
  • Said at least one substance may be selected in the group consisting of:
  • BMP Bone morphogenetic proteins
  • EGF Epidermal growth factor
  • EPO Erythropoietin
  • FGF Fibroplast growth factors
  • G-CSF Granulocyte-colony stimulating factor
  • GM-CSF Granulocyte-macrophage colony stimulating factor
  • GDF-9 Growth differentiation factor-9
  • HGF Hepatocyte growth factor
  • IGF Insuline-like growth factor
  • GDF-8 Myostatin
  • Neurotrophins such as NT-3, NT-4, NT-1 and Nerve growth factor
  • PDGF Platelet-derived growth factor
  • TPO Thrombopoietin
  • TGF- ⁇ Transforming growth factors ⁇ , (TGF- ⁇ ) such as TGF- ⁇ , TGF ⁇ 2,
  • VEGF Vascular endothelial growth factor
  • VEGF-A Vascular endothelial growth factor
  • TNF-a Leukemia inhibitory factor (LIF), interleukin 6 (IL-6), retinoic acid, C SDF-1 (stromal cell-derived factor-1 ), BDNF (brain-derived neurotrophic factor), Periostin, Angiotensin II, Flt3 Ligand, Glial- Derived Neurotrophic Factor, Heparin, Insulin-Like Growth Factor Binding Protein-3, Insulin- Like Growth Factor Binding Protein-5, lnterleukin-3, lnterleukin-8, Midkine, Progesterone, Putrescine, Stem Cell Factor, TGF-alpha, Wntl, Wnt3a, Wnt5a, caspase-4, chemokine ligand 1 , chemokine ligand 2, chemokine ligand 5, chemokine ligand 7, chemokine ligand 1 1 , chemokine ligand 20, haptoglobin, lectin, cholesterol 25-hydroxy
  • the stem cells to be stimulated may be resident cardiac stem cells (CSCs) or circulating stem cells or injected stem cells.
  • Said pharmaceutical composition may comprise primary particles.
  • Said primary particles may be selected from the group consisting of alginates, chitosan, dextran, cellulose, liposome, or microspheres or nanospheres of polyesters such as PLGA, polycaprolactone or copolyesters.
  • said primary particles may encapsulate said at least two stem- cells-stimulating agents of said pharmaceutical composition (B).
  • said primary particles may encapsulate the stem cells-stimulating agents comprised in the pharmaceutical composition (B).
  • the term "primary" means that the pharmaceutical composition may be encapsulated in a first type of particles as defined above.
  • said pharmaceutical composition (B) may be combined with a composition (A) comprising at least one pharmaceutically active substance to form a pharmaceutical cocktail.
  • said at least one pharmaceutically active substance may be selected in the group consisting of insulin-like growth factor 1 (IGF-1 ), hepatocyte growth factor (HGF) and/or variants thereof such as NK1 , 1 K1 , 1 K2, HP1 1 , or HP21 , and combinations thereof.
  • said composition (A) may further comprise SCF-1 .
  • Said composition (A) may further comprise secondary particles selected from the group consisting of alginates, chitosan, dextran, cellulose, liposomes, or microspheres or nanospheres of polyesters such as PLGA, polycaprolactone or copolyesters. Said secondary particles may encapsulate said at least one pharmaceutically active substance.
  • the term "secondary" means that the composition (A) may be encapsulated in a second type of particles as defined above.
  • said secondary particles may be configured to allow a delivery of the substances encapsulated therein before the delivery of the substance encapsulated in primary particles.
  • Said pharmaceutical cocktail may comprise a sample of said composition (B) and a sample of said composition (A).
  • both compositions (A) and (B) may be mixed together in a single sample.
  • compositions (A) and (B) may, however, be administrated to or delivered in the area, or surrounding the area, to be treated separately.
  • Said pharmaceutical composition of the present invention or said pharmaceutical cocktail may be used as medicine.
  • said pharmaceutical composition of the present invention or said pharmaceutical cocktail may be used for the regeneration of cardiac tissue.
  • said pharmaceutical composition of the present invention or said pharmaceutical cocktail may be used for the treatment of heart disease, including heart failure, heart ischemia or myocardial infarction.
  • a process for acting in vivo or ex vivo on CSCs of human or animals comprises the step of administrating said pharmaceutical composition (B) or said pharmaceutical cocktail of the present invention to said humans or animals.
  • the administration of the pharmaceutical composition (B) may follow a preliminary administration of a composition (A) comprising at least one pharmaceutically active substance.
  • the administration may be performed by sequential injection of composition A, B or of the cocktail.
  • the duration between two successive administrations of said pharmaceutical composition or pharmaceutical cocktail of the present invention may be from one hour to 180 days. Each administration may be repeated. Alternatively, each or some administrations of said composition (A) may be optional.
  • said pharmaceutical composition (B) or pharmaceutical cocktail may be administrated parenterally. Moreover, said pharmaceutical composition (B) or pharmaceutical cocktail may be administrated into the circulatory system of a human or animal. Said pharmaceutical composition (B) or pharmaceutical cocktail may be administrated into veins and/or arteries.
  • TGF refers to TGF -1 , TGF -2 or TGF -3 and can be any polypeptide having TGF activity, such as human TGF .
  • TGF can be recombinant TGF .
  • TGF can be TGF -1 .
  • Any appropriate concentration of TGF can be used. For example, between 0.1 and 100 ng of TGF- ⁇ per ml (e.g., about 33 ng of TGF i per ml) can be used.
  • BMP can be any polypeptide having BMP activity, such as human BMP.
  • BMP can be recombinant BMP.
  • BMP can be BMP4. Any concentration of BMP can be used. For example, between 0.1 and 200 ng of BMP per ml (e.g., about 65 ng of BMP4 per ml) can be used.
  • FGF-2 can be any polypeptide having FGF-2 activity, such as human FGF-2.
  • FGF-2 can be recombinant FGF-2. Any concentration of FGF-2 can be used. For example, between 0.1 and 200 ng of FGF-2 per ml (e.g., about 65 ng of FGF-2 per ml) can be used.
  • IGF-1 can be any polypeptide having IGF-1 activity, such as human IGF-1 .
  • IGF-1 can be recombinant IGF-1 . Any concentration of IGF-1 can be used. For example, between 1 and 1000 ng of IGF-1 per ml (e.g., about 650 ng of IGF-1 per ml) can be used.
  • Activin-A can be any polypeptide having Activin-A activity, such as human Activin-A.
  • Activin-A can be recombinant Activin-A. Any concentration of Activin-A can be used. For example, between 0.1 and 500 ng of Activin-A per ml (e.g., about 130 ng of Activin-A per ml) can be used.
  • a-Thrombin can be any polypeptide having ⁇ -thrombin activity, such as human ⁇ -thrombin.
  • ⁇ -thrombin can be recombinant a- thrombin or synthetic a-thrombin. Any concentration of ⁇ -thrombin can be used. For example, between 0.05 and 100 units of ⁇ -thrombin per ml can be used.
  • Cardiotrophin can be any polypeptide having Cardiotrophin activity, such as human Cardiotrophin-1 .
  • Cardiotrophin can be recombinant Cardiotrophin. Any concentration of Cardiotrophin can be used. For example, between 0.05 and 100 ng of Cardiotrophin per ml (e.g., about 13 ng of Cardiotrophin-1 per ml) can be used.
  • IL-6 can be any polypeptide having IL-6 activity, such as human IL-6.
  • IL-6 can be recombinant IL-6. Any concentration of IL-6 can be used. For example, between 10 and 400 ng of IL-6 per ml can be used.
  • Cardiogenol C or a pharmaceutically acceptable salt thereof (e.g., Cardiogenol C hydrochloride) can be used.
  • a pharmaceutically acceptable salt thereof e.g., Cardiogenol C hydrochloride
  • between 1 and 1000 ng of Cardiogenol C per ml e.g., about 350 ng per ml of Cardiogenol C
  • cardiogenol C hydrochloride e.g., Cardiogenol C hydrochloride
  • Retinoic acid can be any molecule having retinoic acid activity, such as synthetic retinoic acid, natural retinoic acid, a vitamin A metabolite, a natural derivative of vitamin A, or a synthetic derivative of vitamin A. Any concentration of retinoic acid can be used. For example, between 1 x 10 "7 and 4 x 10 "6 ⁇ of retinoic acid can be used.
  • serum-containing or serum-free media supplemented with TGF -1 (e.g., 2.5 ng/ml), BMP4 (e.g., 5 ng/ml), FGF-2 (e.g., 5 ng/ml), IGF-1 (e.g., 50 ng/ml), Activin-A (e.g., 10 ng/ml), Cardiotrophin (e.g., 1 ng/ml), a-thrombin (e.g., 1 Unit/ml), and Cardiogenol C (e.g., 100 nM)
  • the media e.g., serum-containing or serum-free media
  • composition used to stimulate CSCs may contain additional optional factors such as TNF-a, LIF, and VEGF-A.
  • TNF-a can be any polypeptide having TNF-a activity, such as human TNF-a.
  • TNF-a can be recombinant TNF-a. Any concentration of TNF-a can be used. For example, between 0.5 and 100 ng of TNF-a per ml can be used.
  • LIF can be any polypeptide having LIF activity, such as human LIF.
  • LIF can be recombinant LIF. Any concentration of LIF can be used. For example, between 0.25 and 200 ng of LIF per ml can be used.
  • VEGF-A can be any polypeptide having VEGF-A activity, such as human VEGF-A.
  • VEGF-A can be recombinant VEGF-A. Any concentration of VEGF-A can be used. For example, between 0.5 and 400 ng of VEGF-A per ml can be used.
  • a composition provided herein can be prepared using any appropriate method.
  • a composition provided herein can be prepared using commercially available stimulating agents.
  • a composition provided herein can be prepared to contain cells lysates (e.g., a platelet lysate) or conditioned media from cells such as cardiomyocyte cells or TNF-a-stimulated endodermal cells.
  • a composition provided herein can be prepared using a platelet lysate supplemented with commercially available factors.
  • a composition provided herein can be prepared using factors isolated from conditioned medium. In some cases, the factors can be dissolved in media such as cell culture media that does or does not contain serum.
  • Tests are performed in acutely infarcted pigs.
  • the following protocol is established.
  • the infarct is performed at TO by 90 minutes left anterior descending (LAD) occlusion followed by a 30 minutes reperfusion.
  • LAD left anterior descending
  • reperfusion T1
  • a primary composition is parenterally administrated to the animals by intracoronary delivery distal to the occlusion site.
  • a BrdU loaded osmotic pump is also subcutaneously implanted at T1 .
  • T2 Fourteen days later (T2), a secondary composition is parenterally administrated to the animals.
  • the administration of both compositions can be achieved with different methods of administration such as intravenous injection, intramuscular injection or intracoronary injection.
  • T3 the euthanasia of the pigs is performed.
  • composition A consists of IGF-1 (8 g in 15ml of Phosphate Buffer
  • Composition B consists of TGF -1 (0.5 pg in 15ml of PBS), BMP4 (1 g in 15ml of PBS), FGF-2 (1 pg in 15ml of PBS), IGF-1 (10 pg in 15ml of PBS), Activin-A (2 g in 15ml of PBS), Cardiotrophin 1 (0.2 g in 15ml of PBS) and Cardiogenol C (5.2 g in 15ml of PBS).
  • compositions are in a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient may be phosphate buffered solution (PBS), Hartmann's solution, Ringer's lactate, physiological NaCI (0.9% NaCI) supplemented or not with albumin or with any suitable protein stabilizer composition.
  • Treatment group 1 is a control group and only receives saline solution at T1 and T2.
  • Treatment group 2 receives a solution containing the composition A at T1 and a saline solution at T2, noted as mix A.
  • Treatment group 3 receives a solution containing the composition A at T1 and a solution containing the composition B at T2, noted mix A+B.
  • Treatment group 4 receives a solution containing the composition B at T1 and T2, noted mix B+B.
  • Treatment group 5 receives a solution containing the composition B at T1 and a saline solution at T2, noted mix B.
  • Blood analyses were performed at different intervals. Blood samples are collected from 2 pigs per treatment group in coronary sinus via jugular vein and venous blood via ear vein. After the primary administration, samples are collected at T1 +5min; T1 +1 h and T1 +6h. After the secondary administration, samples are collected at T2+5min; T2+1 h, T2+6h and T2+24h. ELISA immunoassays are performed with samples for the quantification of IGF-1 and cardiotrophin 1 concentration.
  • Magnetic resonance imaging is also performed on all animals at T1 +3 days; T2 and T3 to study the scar area, the global left ventricular function, the regional function (wall motion and thickening) and regional perfusion of the ventricular.
  • MRI allows to detect and confirm the presence of new vessels, tissue or cells improving ventricular function.
  • Histopathology is also performed to determine the scar area, the identification and quantification of c-kit positive cardiac stem cells. Histopathology also provides data on distribution, size and density of new vessels and cardiomyocytes. Histopathology allows documenting the repair process at the tissue and cellular level.
  • the infarct area was about 19.8% for the control group and about 19% for the group 2 and 4 wherein mix A and mix B+B respectively was used.
  • the infarct area was limited to 13.7% for the group 5 (mix B).
  • the composition (B) according to the present invention was very efficient to treat infarct, such as myocardial infarction, compared to the other composition.
  • Results were compiled separately for sections taken in the border zone or within the central areas of the infarct. Results for all the groups are listed in Table 3 below. Data showed in Table 3 are mean from heart slices analyzed for an animal of each group.
  • the ratio between the infarct and scar size represents the infarct size while the transmurality is a parameter establishing whether the infarct is strongly localized at the external surface of the myocardium or it extends throughout the internal surface of the myocardium. The higher is the transmurality value, the larger is the infarct.
  • composition (B) of the present invention alone or when combined with composition (A) allows limiting the expansion of the infarct to the external surface of the myocardium.
  • pharmaceutical composition and the pharmaceutical cocktail according to the present invention are powerful compositions to treat heart diseases or troubles.
  • both pharmaceutical composition and pharmaceutical cocktail according to the present invention are suitable for the treatment of heart failure secondary to myocardial ischemia, ischemia or myocardial infarction.
  • Tests were performed to evaluate, within the infarct sections, the microvessel density (vWF-positive vessels/mm 2 ), BrdU positive cells and c-kit positive cells.
  • the quantification of microvessel density using von Willebrand factor (vWF) allows determining the amount of new blood vessels created in the infarct zone.
  • BrdU positive cells tests represent the proliferation of cells, including cardiac cells.
  • C-kit positive cells tests show the amount of CSCs within the selected infarct sections. Results are listed in Table 4. These testing were only performed for group 1 (Control group), group 3 (Mix A + B) and group 5 (Mix B). Table 4
  • Results show that when compositions (A) and (B) in combination or composition (B) alone, according to the invention, are injected in the heart, they have great impact on cardiac stem cells stimulation or cardiac cells proliferation. Indeed, microvessel density is enhanced and new blood vessels were created upon stimulation with the present composition or present cocktail. Results obtained with groups 3 or 5 reached 34.2 and 34.3 respectively, compared to 27.9 for the control group. This is confirmed with BrdU positive cells test which shows that cells proliferation was enhanced with the composition of the present invention and that strong cellular activity was observed. When Mix B was injected, 36.0% of BrdU positive cells were observed compared to only 22.1 % for the control group.
  • composition according to the present invention promotes cellular proliferation and thus the formation of new myocytes and vessels with the surrounding myocardium. This can be further enhanced when the pharmaceutical cocktail according to the present invention was used. A value of 52.7% was reached with such cocktail. Hence, both pharmaceutical composition and pharmaceutical cocktail according to the present invention are suitable for improving heart tissue regeneration.
  • C-kit positive cells test allows demonstrating that resident CSCs are consumed since their amount has significantly decreased when mix A+B was used compared to the control group. Hence, the regenerated myocardial structures are originated from resident cardiac stem cells.
  • the present composition and/or cocktail are effective for in vivo stimulation of resident cardiac stem cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet une composition pharmaceutique humaine ou vétérinaire (B) pour la stimulation des cellules souches, comprenant au moins deux agents de stimulation des cellules souches et au moins un excipient pharmaceutiquement acceptable.
PCT/EP2010/068700 2009-12-02 2010-12-02 Compositions pharmaceutiques pour la stimulation des cellules souches WO2011067317A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2781493A CA2781493A1 (fr) 2009-12-02 2010-12-02 Compositions pharmaceutiques pour la stimulation des cellules souches
RU2012120834/15A RU2012120834A (ru) 2009-12-02 2010-12-02 Фармацевтические композиции для стимулирования стволовых клеток
CN201080053800XA CN102711798A (zh) 2009-12-02 2010-12-02 刺激干细胞的药物组合物
MX2012005976A MX2012005976A (es) 2009-12-02 2010-12-02 Composiciones farmaceuticas para la estimulacion de los citoblastos.
EP10790375.9A EP2506867B1 (fr) 2009-12-02 2010-12-02 Compositions pharmaceutiques pour la stimulation des cellules souches
NZ599930A NZ599930A (en) 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells.
AU2010326633A AU2010326633A1 (en) 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells.
JP2012541498A JP2013512877A (ja) 2009-12-02 2010-12-02 幹細胞の刺激のための医薬組成物
BR112012013164A BR112012013164A2 (pt) 2009-12-02 2010-12-02 composições farmacêuticas para o estímulo de células-tronco
IL219901A IL219901A0 (en) 2009-12-02 2012-05-20 Pharmaceutical composiitons for the stimulation of stem cells
US13/484,956 US20120301538A1 (en) 2009-12-02 2012-05-31 Pharmaceutical compositions for the stimulation of stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2009066251 2009-12-02
EPPCT/EP2009/066251 2009-12-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/484,956 Continuation US20120301538A1 (en) 2009-12-02 2012-05-31 Pharmaceutical compositions for the stimulation of stem cells

Publications (1)

Publication Number Publication Date
WO2011067317A1 true WO2011067317A1 (fr) 2011-06-09

Family

ID=42316097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068700 WO2011067317A1 (fr) 2009-12-02 2010-12-02 Compositions pharmaceutiques pour la stimulation des cellules souches

Country Status (12)

Country Link
JP (1) JP2013512877A (fr)
KR (1) KR20120099751A (fr)
CN (1) CN102711798A (fr)
AU (1) AU2010326633A1 (fr)
BR (1) BR112012013164A2 (fr)
CA (1) CA2781493A1 (fr)
IL (1) IL219901A0 (fr)
MX (1) MX2012005976A (fr)
NZ (1) NZ599930A (fr)
RU (1) RU2012120834A (fr)
TW (1) TW201141510A (fr)
WO (1) WO2011067317A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2634576C1 (ru) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ стимуляции регенерации тканей
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro
WO2021187895A1 (fr) * 2020-03-17 2021-09-23 주식회사 히에라바이오 Composition pour la prévention ou le traitement de maladies ischémiques comprenant des cellules souches cardiaques

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456676B (zh) * 2014-07-07 2021-07-23 米迪波斯特股份有限公司 经刺激的干细胞的培养基的毛发生长促进功能及其用途
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
KR102106710B1 (ko) 2018-10-11 2020-05-04 강원대학교산학협력단 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015127A2 (fr) * 2004-07-30 2006-02-09 Mayo Foundation For Medical Education And Research Traitement de tissu cardio-vasculaire
WO2006081190A2 (fr) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions et methodes de traitement de troubles cardiaques
US20080019944A1 (en) * 2006-07-24 2008-01-24 Mayo Foundation For Medical Education And Research Methods and Materials for Providing Cardiac Cells
US20090155344A1 (en) * 2007-12-13 2009-06-18 Beijing Shengyiyao Science & Technology Development Co., Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015127A2 (fr) * 2004-07-30 2006-02-09 Mayo Foundation For Medical Education And Research Traitement de tissu cardio-vasculaire
WO2006081190A2 (fr) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions et methodes de traitement de troubles cardiaques
US20080019944A1 (en) * 2006-07-24 2008-01-24 Mayo Foundation For Medical Education And Research Methods and Materials for Providing Cardiac Cells
US20090155344A1 (en) * 2007-12-13 2009-06-18 Beijing Shengyiyao Science & Technology Development Co., Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
AMADO ET AL., PROC NATL ACAD SCI USA, vol. 102, 2005, pages 11474 - 11479
BALSAM ET AL., NATURE, vol. 428, 2004, pages 668 - 673
BARTUNEK JOZEF ET AL: "Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium", AMERICAN JOURNAL OF PHYSIOLOGY - HEART AND CIRCULATORY PHYSIOLOGY, vol. 292, no. 2, February 2007 (2007-02-01), pages H1095 - H1104, XP002592697, ISSN: 0363-6135 *
BEARZI ET AL., PROC NATL SCI USA, vol. 104, 2007, pages 14068 - 14073
BEHFAR ATTA ET AL: "Cardiopoietic programming of embryonic stem cells for tumor-free heart repair", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 204, no. 2, 1 February 2007 (2007-02-01), pages 405 - 420, XP002462528, ISSN: 0022-1007, DOI: DOI:10.1084/JEM.20061916 *
BEHFAR ATTA ET AL: "Guided Cardiopoiesis Enhances Therapeutic Benefit of Bone Marrow Human Mesenchymal Stem Cells in Chronic Myocardial Infarction", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 56, no. 9, August 2010 (2010-08-01), pages 721 - 734, XP002623549, ISSN: 0735-1097 *
BELTRAMI ET AL., CELL, vol. 114, 2003, pages 763 - 776
CHO ET AL., J EXP MED, vol. 204, 2007, pages 3257 - 3269
DIMMELER S. ET AL., J CLIN INVEST, vol. 11, 2005, pages 572 - 583
KAJSTURA ET AL., CIRC. RES., vol. 96, 2005, pages 127 - 137
MIN ET AL., ANN THOR SURG, vol. 74, 2002, pages 1568 - 1575
MURRY ET AL., NATURE, vol. 428, 2004, pages 664 - 668
NYGREN ET AL., NAT MED, vol. 10, 2004, pages 494 - 501
ORLIC ET AL., NATURE, vol. 410, 2001, pages 701 - 705
ROTA ET AL., PROC NATL ACAD SCI USA, vol. 104, 2007, pages 17783 - 17788
SCHUH ET AL., BASIC RES CARDIOL, vol. 103, 2008, pages 60 - 77
TOKUNOU TOMOTAKE ET AL: "Engineering a new insulin-like growth factor-1 protein for embryonic stem cell therapy", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 114, no. 18, suppl. S, 1 October 2006 (2006-10-01), pages 239, XP009124938, ISSN: 0009-7322 *
TORELLA DENISE ET AL: "Cardiac stem cells regenerate the infarcted heart, restoring function and long-term survival in mice", CIRCULATION, vol. 110, no. 17, Suppl. S, October 2004 (2004-10-01), & 77TH SCIENTIFIC MEETING OF THE AMERICAN-HEART-ASSOCIATION; NEW ORLEANS, LA, USA; NOVEMBER 07 -10, 2004, pages 170, XP009136301, ISSN: 0009-7322 *
URANEK ET AL., PROC NATL SCI USA, vol. 103, 2006, pages 9226 - 9231

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2634576C1 (ru) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ стимуляции регенерации тканей
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro
WO2021187895A1 (fr) * 2020-03-17 2021-09-23 주식회사 히에라바이오 Composition pour la prévention ou le traitement de maladies ischémiques comprenant des cellules souches cardiaques

Also Published As

Publication number Publication date
AU2010326633A1 (en) 2012-05-31
TW201141510A (en) 2011-12-01
KR20120099751A (ko) 2012-09-11
NZ599930A (en) 2014-04-30
RU2012120834A (ru) 2014-01-20
JP2013512877A (ja) 2013-04-18
IL219901A0 (en) 2012-07-31
BR112012013164A2 (pt) 2016-03-01
CN102711798A (zh) 2012-10-03
MX2012005976A (es) 2012-06-25
CA2781493A1 (fr) 2011-06-09

Similar Documents

Publication Publication Date Title
EP2506867B1 (fr) Compositions pharmaceutiques pour la stimulation des cellules souches
WO2011067317A1 (fr) Compositions pharmaceutiques pour la stimulation des cellules souches
Kawamoto et al. Nerve growth factor and wound healing
KR101689415B1 (ko) 심장병 치료를 위한 약제학적 조성물
Shyu et al. Homing genes, cell therapy and stroke
Song et al. Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP
WO2004009767A2 (fr) Therapie cellulaire de regeneration
US20060110374A1 (en) Method to accelerate stem cell recruitment and homing
Zisa et al. Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells
Hwang et al. Improving regenerating potential of the heart after myocardial infarction: factor-based approach
KR20030034177A (ko) 허혈성 질환 치료제
JP2013512877A5 (fr)
JP2007525444A5 (fr)
Louzada et al. Granulocyte-colony stimulating factor treatment of chronic myocardial infarction
Cho et al. Enhancement of angiogenic efficacy of human cord blood cell transplantation
Jeon et al. Synergistic effect of sustained delivery of basic fibroblast growth factor and bone marrow mononuclear cell transplantation on angiogenesis in mouse ischemic limbs
Bulgin Therapeutic angiogenesis in ischemic tissues by growth factors and bone marrow mononuclear cells administration: biological foundation and clinical prospects
Pattar et al. Application of bioengineered materials in the surgical management of heart failure
CZ20023426A3 (cs) Přípravek mající mobilizační aktivitu
EP2308502A1 (fr) La méthode pour induire la néovascularisation et la régénération de tissus
EP2432482B1 (fr) Composition pharmaceutique pour le traitement de cardiopathies
Davis The cell engraftment hypothesis of cardiac repair
JP6923137B2 (ja) 組織治癒剤
Širmenis et al. Recovery of infarcted myocardium in an in vivo experiment
JPWO2006046766A1 (ja) 心不全治療のための遺伝子治療

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080053800.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790375

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010326633

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2012541498

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2781493

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 219901

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/005976

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 4687/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010326633

Country of ref document: AU

Date of ref document: 20101202

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127017238

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012120834

Country of ref document: RU

Ref document number: 2010790375

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012013164

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012013164

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120531